000			03129nam a2200601 i 4500
001			on1305944541
003			EBZ
005			20251029164100.0
006			m d
007			cr |||||||||||
008			220311s2022 flu ob 001 0 eng
010			_a 2021059396
040			_aEBZ _beng _cEBZ
020			_a9781000594676 _q(epub)
020			_a100059467X
020			_a9781003048565 _q(ebook)
020			_a1003048560
020			_a9781000594638 _q(electronic bk.)
020			_a1000594637 _q(electronic bk.)
020			_z9780367500269 _q(paperback)
020			_z9780367500290 _q(hardback)
042			_apcc
050	0	0	_aRA410.5
049			_aMAIN
100	1		_aToumi, Mondher, _eauthor. _964240
245	1	0	_aManaged entry agreements and funding for expensive therapies / _cMondher Toumi, Szymon Jaroslawski.
250			_aFirst edition.
264		1	_aBoca Raton : _bCRC Press, _c2022.
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
341	0		_atextual _2sapdv _3EBSCOhost
490	0		_aPharmaceuticals, health economics and market access
532		0	_3EBSCOhost _a"EBSCO evaluates our products based on the Web Content Accessibility Guidelines (WCAG) and the related Section 508 and EN 301 549 regulations in the US and EU. Most EBSCO products are substantially conformant with WCAG 2.2 level AA." Source: https://connect.ebsco.com/s/article/EBSCO-VPATs?language=en_US. Last accessed April 22, 2025.
588			_aDescription based on print version record and CIP data provided by publisher.
504			_aIncludes bibliographical references and index.
505	0		_aIntroduction to managed entry agreements -- From coverage with evidence development to individual performance-based agreements in Italy -- Coverage with evidence development for multiple sclerosis drugs in the UK -- a "costly failure"? -- Novel funding models for expensive therapies -- Definition and classification of MEAs -- Country comparison of the implementation of managed entry agreements.
520			_a"Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable"-- _cProvided by publisher.
650		0	_aMedical care _xCost control. _964241
650		0	_aDrugs _xTesting. _964242
650		0	_aDrugs _xPrices. _964243
650		0	_aDrug accessibility. _964244
655		4	_aElectronic books. _958574
700	1		_aJaroslawski, Szymon, _eauthor. _964245
776	0	8	_iPrint version: _aToumi, Mondher. _tManaged entry agreements and funding for expensive therapies _bFirst edition. _dBoca Raton : CRC Press, 2022 _z9780367500269 _w(DLC) 2021059395
856	4	0	_3EBSCOhost _uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3282745
938			_aYBP Library Services _bYANK _n302877341
938			_aEBSCOhost _bEBSC _n3282745
994			_a92 _bN$T
999			_c55949 _d55949